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INTRODUCTION
Tuberculosis (TB) is a contagious disease initiated by inhalation
of airborne droplets with live Mycobacterium tuberculosis
coughed out by patients with active TB infection. In most infected
persons, localized immune responses can clear the bacteria or
encapsulate it in granulomas, and active disease is prevented [1,2].
Some live M. tuberculosis may, however, survive inside granulo-
mas, and can cause subsequent reactivation of disease, particu-
larly if the immune system is suppressed. Almost one third of all
humans are estimated to be infected with M. tuberculosis. Three
million people die of TB and 8 million fresh cases are detected
each year, making it one of the most serious global health prob-
lems [3]. The only vaccine available for TB is BCG (M. bovis,
Bacillus Calmette-Guerin). Its efficacy has been variable, ranging
from 0% to 80% in different studies [4,5]. Development of an
effective vaccine against TB is hampered by the lack of clear
understanding about the mechanism of protective immunity.
A substantial body of literature exists documenting immune
responses to systemic challenge with mycobacteria in murine
models [6–8]. However, it has been demonstrated that immune
responses to systemic and lung infections with mycobacteria are
substantially different. For example, mice are almost 100-fold
more susceptible to infection initiated in lungs than infection ini-
tiated systemically [9]. Since lungs are the portal of entry and the
most common site of clinically-apparent TB, it is important to
understand the nature of immune responses to mycobacterial
infection in lungs. The mouse model of BCG infection in lungs
resembles human infection in as much as the infection is effec-
tively contained. Protective immune responses in this model are
beginning to be elucidated [10–13]. It is known that infection
peaks at 4–6 weeks after intratracheal (IT) deposition of BCG,
and there is an associated surge in T cells in the lung interstitium
[10,11]. Broncho-alveolar lavage (BAL) contains increased levels
of cytokines associated with T-helper (Th)1-type responses, such
as IFNg, IL12 and TNFa [11]. Crucial roles of type I cytokines,
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SUMMARY
Gamma interferon (IFNg) plays a key role in host defense against pulmonary mycobacterial infections.
A variety of lymphocyte subsets may participate in producing pulmonary IFNg responses, but their 
relative contributions after mycobacterial infection have not been clearly elucidated. To address this
question, C57Bl/6 female mice were infected by intrapulmonary instillation of 2·5 ¥ 104 BCG (Mycobac-
terium bovis Bacillus Calmette-Guerin). Lymphocyte populations in lung interstitium were examined
at different time points after the infection. BCG load in lungs peaked between 4 and 6 weeks post-
infection and declined to very low levels by the 12th week of infection. Recovery of lung interstitial
lymphocytes doubled by 4–6 weeks after infection and declined thereafter. Flow cytometric analysis of
the lung-derived lymphocytes revealed that about 5% of the these cells made IFNg in control mice, and
this baseline IFNg production involved T (CD3+NK1.1-), NK (CD3-NK1.1+) and NKT (CD3+NK1.1+)
cells. As the BCG lung infection peaked, the total number of CD3+ T cells in the lungs increased three-
fold at 5–6 weeks post-infection. There was a marked increase (sixfold) in the number of T cells secret-
ing IFNg 5–6 weeks post-infection. Some increase was also noted in the NKT cells making IFNg, but
the numbers of NK cells making IFNg in BCG-infected lungs remained unaltered. Our results suggest
that whereas NK and NKT cells contribute to baseline IFNg secretion in control lungs, expansion in
the IFNg-producing T-cell population was essentially responsible for the augmented response seen in
lungs of BCG-infected mice.
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especially IFNg in anti-mycobacterial immunity, have been
demonstrated using immunodeficient knockout and transgenic
mouse models [11,13–19]. Many types of immune cells, like T
cells, NK cells and macrophages, can produce Th1 cytokines 
or cytokines supportive of Th1 responses. The kinetics of activa-
tion and accumulation of these cells in lungs of infected mice is
not clearly understood. Moreover the relative contribution of 
different lymphocyte subsets to secretion of Th1 cytokines is
unknown.
Our specific aims, therefore, were to document the kinetics of
changes in lymphocyte subpopulations after murine pulmonary
BCG infection, and to identify cell populations responsible for
IFNg responses. Our results suggest that significant numbers of T,
NK and NKT cells in lung interstitium of uninfected control mice
make IFNg. In mice with BCG lung infection, however, aug-
mented IFNg production in response to BCG occurs primarily in
the T-cell population.
MATERIALS AND METHODS
Animals
C57Bl/6 female mice 12–15 weeks of age were obtained from
Jackson Laboratories, Bar Harbor, ME, and used between 18 and
30 weeks of age. Mice were maintained in filter-topped cages pro-
vided with HEPA-filtered air in the animal facilities at NIOSH.
All studies were reviewed and approved by the NIOSH Institu-
tional Animal Care and Use Committee.
Reagents
Percoll, phorbol 12-myristate 13-acetate (PMA), ionomycin, col-
lagenase (cat no. C5138), DNAse (cat. no. D4263), hyluronidase
(cat no. H3506), elastase (cat no. E0258), goat-anti-mouse Ig-
FITC (specific for Fab) and RPMI 1640 culture medium were
bought from Sigma, St Louis, MO, USA. Monoclonal antibodies
(MoAbs) labelled with FITC, PE or PerCP [anti-CD3 (Clone
17A2); anti-NK1.1 (clone PK136); anti-CD16/32 (Fc-block, 
clone 2.4G2); anti-mouse IFNg (clone XMG1.2)] and their res-
pective isotypic controls were obtained from Pharmingen
(Pharmingen/Becton Dickinson, San Diego, CA, USA). Middle-
brook culture medium and supplements were obtained from
Becton Dickinson Microbiology Systems, Sparks, MD, USA.
BCG and interpulmonary instillation
A seed culture of BCG (M. bovis Pasteur, TMCC no. 1011) was
kindly provided by Prof. Ian Orm of the Microbiology Depart-
ment, Colorado State University, Fort Collins, CO. BCG was
grown in Middlebrook culture medium with OADC supplement
and Tween. Viable BCG suspensions were counted by plating
bacterial suspensions at different dilutions on Middlebrook agar
plates and counting colonies after 2 weeks. Mice were anaes-
thetized by i.p. administration of 0·15 ml of a solution containing
Ketamine HCl (8·3 mg/ml) and Xylazine (0·33 mg/ml), and BCG
suspension (50 ml bacterial suspension containing 2·5 ¥ 104 bacte-
ria/mouse) was instilled into the lungs of C57Bl/6 mice by the
method described by Keane-Myers et al. [20]. An equal volume
of phosphate-buffered saline (PBS) was similarly administered
into control C57Bl/6 mice.
Processing of tissues
Mice were sacrificed by pentobarbital overdose. In order to min-
imize contamination of lung interstitial leucocyte preparations by
blood-derived cells, lungs were perfused with PBS via the right
atrium before their removal. Isolation of lung interstitial cells was
done by enzymatic digestion of lung tissue, mechanical dispersion,
and separation on a discontinuous Percoll gradient essentially as
described by Wakeham et al. [11] with minor modifications. Lung
tissue was chopped into small pieces (1–2 mm) and incubated 
in a solution containing collagenase (150 U/ml), DNAse 
(20 Kunitz/ml), hyaluronidase (35 U/ml) and elastase (0·2 U/ml) in
PBS, for 90 min on a rocking platform at 37°C. Digested lung
tissue was pressed through a stainless steel mesh. A small aliquot
of the suspension for each lung preparation was taken for BCG
count and the rest used for isolation of lymphocytes by Percoll
density gradient centrifugation [11].
Flow cytometry
Cells derived from lungs were stained with MoAbs against several
membrane markers as well as against IFNg to detect cytoplasmic
IFNg. Cells were distributed at 0·2–0·3 ¥ 106 per well of a deep
96-well plate. Cells were washed twice with staining buffer (1%
FCS and 0·1% sodium azide in PBS). They were then suspended
in 20 ml staining buffer containing 1 mg anti-CD16/32 MoAb (Fc-
Block) and incubated at room temperature for 20 min. Staining
MoAbs (1 mg in 20 ml staining buffer) were then added and incu-
bation continued for an additional 30 min at room temperature in
the dark. Cells were washed twice with staining buffer and fixed
by adding 0·1 ml 0·4% paraformaldehyde solution to the loosened
pellets of stained cells. For cytoplasmic staining for IFNg, 0·3–0·5
¥ 106 cells in 200 ml CM were cultured for 4 h with 50 ng/ml PMA
and 500 ng/ml ionomycin. Fixing/permeabalization and staining of
cells for cytoplasmic IFNg and membrane markers for T or NK
cells was done using a kit and the protocol recommended by the
manufacturer (Pharmingen). Cells were analysed on a Becton
Dickinson FACSCalibur flow cytometer. Cells stained with iso-
typic control antibodies were used to demarcate the lymphocyte
window, as well as to set gates for discrimination between cells
with or without specific stain.
Statistical analysis
Two-way comparisons were performed using Student’s t-test.
Multiple comparisons were performed by analysis of variance.
Comparisons were made using computer software (Sigmastat,
SPSS, Chicago, IL, USA). Comparisons were considered signifi-
cantly different at a level of P < 0·05.
RESULTS
Recovery of lung interstitial lymphocytes from BCG-infected
C57Bl/6 mice
BCG suspension or an equal volume of PBS was instilled in lungs
of C57Bl/6 mice. As described in previous studies [10,11], BCG
load in the lungs increased and peaked between 4 and 6 weeks
post-infection and fell thereafter (results not shown). By the 12th
week after infection, BCG were essentially cleared from lungs.
Average lymphocyte recovery from control mice ranged between
2 and 3 ¥ 106 cells/lung. At each time point, the recovery of lung
interstitial lymphocytes in an infected group of mice was com-
pared with the corresponding recoveries from control PBS-
instilled mice. Results in Table 1 indicate that leucocyte recovery
from lungs of infected mice was significantly greater than the
control recoveries at 5, 6 and 8 weeks after infection. Maximum
increase of about 130% was seen at the 5th week post-infection
(Table 1).
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Lymphocyte sub-populations in the lungs of 
BCG-infected mice
Flow cytometric analysis was used to enumerate lymphocyte sub-
populations in lungs at each time point. For all phenotypic studies,
a lymphocyte gate was set on the forward/side scatter plot (Fig.
1a). Cells were stained and analysed for a variety of phenotypic
markers. Results in Fig. 1 show a set of typical flow cytometry
results of cells double-stained for CD3 and NK1.1 markers (Fig.
1b), CD4 and CD8 markers (Fig. 1c), and CD3 and cytoplasmic
IFNg (Fig. 1d). Significant variations were found in the propor-
tions of various lymphocyte sub-populations derived from lungs.
Data in Table 2 show the average representation of T, NK, NKT,
B and gdT cells in lung interstitial cell preparations derived from
control mice. The average CD4/CD8 cell ratio and its range is also
given in Table 2.
Knowing the values of total cell recovery from lungs and per-
centage of a particular cell sub-population by flow cytometry,
absolute numbers of lymphocyte sub-populations per lung could
be computed. Absolute numbers of T cells (CD3+), NK cells
(NK1.1+), T cells with cytoplasmic IFNg (CD3+IFNg+) and non-T
cells with cytoplasmic IFNg (CD3-IFNg+) in lungs of control and
BCG-infected mice at different time points after infection are
shown in Fig. 2. These results indicate that absolute numbers of
CD3+ and NK1.1+ cells per lung increased significantly in BCG-
infected mice, specifically 5 and 6 weeks post infection (Fig. 2). A
marked increase in the CD3+IFNg+ population occurred in BCG-
infected mice (Fig. 2c), maximum increase being about sixfold 5–6
weeks post-infection. The extent of increase in CD3+IFNg+ cells
was greater than the increase in total CD3+ cells (about threefold)
in BCG-infected mice. Interestingly, a significant number of CD3-
cells derived from control or BCG-infected mice were positive for
cytoplasmic IFNg (Fig. 2d). These results suggest that non-T cells
(e.g. NK cells) may contribute to IFNg production in control 
and BCG-infected mouse lungs. No significant change was
observed in the relative proportions of gdT cells and B cells, and
in CD4/CD8 ratios in lymphocyte preparations derived from
control or BCG-infected mouse lungs (results not shown).
While CD3+ cells secreting IFNg increased considerably 
in BCG-infected lungs (Fig. 2), these could include NKT
(CD3+NK1.1+) cells, whose contribution, if any, to IFNg secretion
could not be assessed by these results. Three-colour flow cyto-
metric analysis was carried out to further characterize the cells
which make IFNg, and to assess the relative contributions of T
and non-T cells to IFNg production in lung cells derived from
control and BCG-infected (5 week post-infection) mice. For this
purpose, lung cells were stained with anti-CD3 (perCP), anti
NK1.1 (FITC) and anti-IFNg (PE) antibodies. From the CD3
versus NK 1.1 plots, gates were put on NK cells (CD3-NK1.1+), T
cells (CD3+NK1.1-) and NKT (CD3+NK1.1+) cells, and these three
populations were further analysed for cytoplasmic staining for
IFNg. Results of these experiments summarized in Table 3 indi-
cate that on average, absolute numbers of T cells (CD3+NK1.1-)
as well as T cells making IFNg (CD3+NK1.1-IFNg+ population)
increased by three- and sevenfold, respectively. While absolute
numbers of NK cells (NK1.1+CD3-) per lung increased in BCG-
infected mice, numbers of IFNg-producing NK cells (CD3-
NK1.1+IFNg+ population) remained unaltered (Table 3). NKT
cells (NK1.1+CD3+) constituted a small population in control as
well as BCG-infected lungs, yet absolute numbers of IFNg-
producing NKT cells (CD3+NK1.1+IFNg + population) appear to
increase in BCG-infected lungs (Table 3).
DISCUSSION
Most people exposed to M. tuberculosis can effectively fight the
infection, and it is only a small fraction of infected persons that
develops active disease. The mouse model of BCG lung infection
© 2002 Blackwell Science Ltd, Clinical and Experimental Immunology, 128:405–410
Table 1. Recovery of lung cells from control and BCG-infected mice
Lung cells recovery Lung cell recovery
Duration of infection from PBS-instilled mice from BCG-instilled mice
(weeks) (¥106/lung) + s.d. (¥106/lung) + s.d. Percent increase
2 2·30 + 0·63 3·06 + 0·58 33·0
4 2·36 + 0·41 3·17 + 0·36 34·3
5 2·50 + 0·43 5·79 + 0·87 131·6*
6 2·34 + 0·76 4·80 + 0·86 93·5*
8 2·94 + 0·88 4·76 + 0·83 61·9*
12 2·62 + 0·60 3·72 + 0·83 42·0
BCG (2·5 ¥ 104/mouse) or PBS was instilled in lungs of C57Bl6 mice. At each time point after
BCG/PBS instillation, lung lymphocytes were isolated from 5–9 control and BCG-infected mice.
*P < 0·05.
Table 2. Representation of various lymphocyte sub-populations in lung
interstitial cell preparations
Average representation* (%)
Cell population Mean + s.d. Range
T cells (CD3+NK1.1-) 24·3 + 2·90 (34)† 18·1–31·1
NK cells (CD3-NK1.1+) 18·8 + 3·84 (28) 8·9–25·1
NKT cells (CD3+NK1.1+) 2·2 + 0·73 (18) 1·0–3·5
B cells (sIg+) 42·7 + 2·36 (5) 42·7–49·0
gd T cells 1·89 + 0·43 (15) 1·2–2·6
CD4/CD8 ratio 1·20 + 0·21 (20) 1·0–1·9
*Cell preparations derived from lungs were stained for various given
markers and analysed on a flow cytometer.
†Number of cell preparations analysed.
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Fig. 1. Representative flow cytometric results showing discrimination of various cell sub-populations in interstitial cell preparations derived
from normal mouse lungs. The lymphocyte gate used is shown in (a). Lung cells were stained with different pairs of phenotyping anti-
bodies, CD3 and NK1.1 markers (b), CD4 and CD8 markers (c), CD3 and cytoplasmic IFNg (d). Antibodies were tagged with FITC (x
axis) and PE (y axis).
Table 3. Effect of BCG lung infection on IFNg production by different lymphocyte sub-populations in lung interstitium of C57Bl/6 mice
Total lung
Cell sub-population
Percent cells IFNg-producing 
cell recovery Percentage of Cells/lung with cytoplasmic cells per lung
Treat-ment (¥106) Sub-population Phenotype lung cells (¥105) IFNg (¥105)
PBS 2·52 + 0·41 T cells CD3+NK1·1- 25·44 + 3·71 6·53 + 1·84 17·03 + 4·66 1·06 + 0·15
NK cells CD3-NK1·1+ 12·88 + 4·04 3·13 + 0·58 33·06 + 5·58 1·04 + 0·25
NKT cells CD3+NK1·1+ 1·30 + 0·20 0·33 + 0·05 50·65 + 16·54 0·16 + 0·05
BCG 6·57 + 0·68 T cells CD3+NK1·1- 33·00 + 0·87 21·68 + 1·93 33·14 + 5·58 7·01 + 1·64*
NK cells CD3-NK1·1+ 9·48 + 1·78 6·32 + 1·78 15·94 + 4·46 0·95 + 0·08
NKT cells CD3+NK1·1+ 2·14 + 0·45 1·40 + 0·27 32·23 + 10·45 0·50 + 0·10*
Lung cells were prepared from control (PBS-instilled) or BCG-infected mice (5 week post-infection) as described in Materials and Methods. Cells
were membrane-stained with anti-CD3-PerCP and anti-NK1.1-FITC antibodies followed by intercellular staining with anti-IFN-PE antibody. Relative
proportions of NK, T and NKT populations were obtained from two-colour dot matrix plot (FITC versus PerCP). These populations were further gated
and analysed individually for staining with intercellular IFN (third colour, PE). Relative proportions of different cell populations and their absolute
numbers in lungs were calculated. All values are mean + s.d. of four independent experiments. *P < 0·05 (difference between control and BCG groups).
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resembles human TB in that the infection is self-limiting. Some
information is available in the literature about the cellular basis
of lung immunity against BCG infection in mouse lungs [10–13].
An increase in T cells in lung interstitium, and elevated Th1
cytokines like IFNg, TNFa and IL12 in BAL, have been demon-
strated [11]. IFNg appears to have a crucial role in innate as well
as acquired immunity against mycobacterial immunity [13–18]. T
cells and NK cells are two prominent cell types which have the
ability to secrete IFNg, but their relative contribution to the IFNg
response in mycobacterial infection is not clear. IL-15 transgenic
mice were recently shown to have elevated levels of NK cells as
well as IFNg levels, and were relatively resistant to mycobacter-
ial infection [19]. Interestingly, depletion of NK cells as well as T
cells in IL-15 transgenic mice resulted in increased susceptibility
to BCG [19], indicating that both cell types may have an impor-
tant role in anti-mycobacterial immunity. In the present study, our
primary aim was to delineate the kinetics of accumulation of dif-
ferent lymphocyte subsets in the lungs of BCG-infected mice, and
to identify cells containing IFNg in their cytoplasm, as these cells
are expected to secrete the cytokine.
As documented in previous reports [10,11], peak bacterial
load in lungs was attained between 4 and 6 weeks and declined to
very low levels by the 12th week of infection. These results would
suggest that protective immune responses in lungs become effec-
tive from the 4th week onwards. Timing of initiation of protective
immunity in lungs is also suggested by the kinetics of lymphocyte
influx into the lungs. By the 5th and 6th week after infection,
recovery of lymphocytes from BCG-infected lungs was double
that from control lungs. The relative proportion of NK cells
(NK1.1+) in lung interstitium (Table 2,3) is significantly higher
than the proportion of these cells in spleen (range 1–3%, results
not shown). These results corroborate the previously reported
higher levels of NK activity in mouse lungs as compared with
spleen [21]. Our results further show that about 5% of the lung
interstitial lymphocytes from control mice make IFNg (Table 3),
and NK as well as T cells contribute to IFNg in equal proportion
in control lungs (Table 3). Production of IFNg in control lungs
could be spontaneous, or a consequence of exposure to environ-
mental antigens, or both. It is possible that one of the purposes
of high accumulation of NK cells in lung interstitium is to secrete
and maintain a certain basal level of IFNg in order to afford pro-
tection from viral and other infectious agents commonly encoun-
tered in lungs. NK cells are known to play an important role in
natural immunity [22], and our results support a similar role for
NK cells in lungs. Additionally, IFNg secretion could have other
homeostatic functions, like sustaining a basal level of nitric oxide
synthase activity in airway epithelial cells [23].
After BCG infection, the IFNg-producing cell population
expands and at the peak of infection (5 weeks post-infection),
about 13% of lung-derived cells are positive for cytoplasmic 
IFNg (Table 2). Since there is a significant increase in total 
lymphocytes recovered from infected lungs, absolute numbers of
IFNg-producing cells per lung increase about fourfold. Almost all
the increase in IFNg production in BCG-infected lungs appears
to be due to expansion of an IFNg-producing subset of T 
lymphocytes, which increase about sevenfold, whereas the
number of NK cells making IFNg in BCG-infected lungs is not
significantly different from the corresponding numbers in control
lungs. Absolute numbers of NKT cells making IFNg in BCG-
infected mice appears to increase even though the relative 
contribution of NKT cells as a source of IFNg remains low in
BCG-infected mice.
The important role of IFNg as a component of protective
immunity to mycobacterial infections is well established
[14,17].We have demonstrated that T, NK and NKT cells in the
lung may participate in maintaining a base line IFNg secretion in
control lungs. An adaptive immune response to BCG in terms of
IFNg production is, however, almost entirely due to an expansion
of IFNg-producing T cells.
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Fig. 2. Kinetics of changes in the absolute recoveries of total CD3+ and
NK1.1+ lymphocytes as well as CD3+IFNg + and CD3-IFNg + lymphocytes
from the lungs of control and BCG-infected mice. In each panel, closed
circles denote the cell recoveries per lung from control mice and open
circles represent the corresponding recoveries from mice infected with
BCG. Each value of cell recovery is a mean + s.d. of five observations. BCG
group difference from the control group by applying unpaired t-test was
P < 0·05* or P < 0·001**. (a) CD3+ cells; (b) NK1.1+ cells; (c) CD3+IFNg
cells; (d) CD3-IFNg cells.
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